Quantcast
Last updated on April 21, 2014 at 4:56 EDT

Collegium Pharmaceutical to Present at Piper Jaffray’s 24th Annual Healthcare Conference

November 27, 2012

CUMBERLAND, R.I., Nov. 27, 2012 /PRNewswire/ — Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, is pleased to announce it will present at Piper Jaffray’s 24(th) Annual Healthcare Conference, taking place at the Palace Hotel in New York City from November 27 – 28, 2012.

Collegium President and CEO, Michael Heffernan, is scheduled to present at 1:30PM on Wednesday, November 28(th).

About DETERx(®) Technology

The DETERx(®) drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide tamper-resistant properties to protect against common methods of tampering such as chewing, crushing, snorting and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastronomy tube, while maintaining the extended release properties of the product. DETERx(®) technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. COL-003 is the first of a number of product candidates using the DETERx(®) platform.

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx(®) formulation platform for the treatment of chronic pain. The DETERx(®) oral drug delivery technology provides extended-release delivery, unique tamper-resistant properties, and flexible dose administration options. For more information, visit the Company’s website at www.collegiumpharma.com.

Contact:

Michael Heffernan, President
Collegium Pharmaceutical, Inc.
401-762-2000, x220
mheffernan@collegiumpharma.com

SOURCE Collegium Pharmaceutical, Inc.


Source: PR Newswire